Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Thank you and see you in 2023

Grady Wulff
December 20, 2022

Weekly Wrap 16 December

Grady Wulff
December 16, 2022

Morning Bell 16 December

Bell Direct
December 16, 2022

Closing Bell 15 December

Grady Wulff
December 15, 2022

Morning Bell 15 December

Grady Wulff
December 15, 2022

Closing Bell 14 December

Grady Wulff
December 14, 2022

Morning Bell 14 December

Grady Wulff
December 14, 2022

Closing Bell 13 December

Grady Wulff
December 13, 2022

Morning Bell 13 December

Sophia Mavridis
December 13, 2022

Closing Bell 12 December

Grady Wulff
December 12, 2022

Morning Bell 12 December

Grady Wulff
December 12, 2022

Weekly Wrap 9 December

Grady Wulff
December 9, 2022